At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 39 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
In Brief
A Phase 3 clinical trial evaluating Placebo and Lumasiran for Primary Hyperoxaluria Type 1 (PH1). Completed, enrolled 39 participants across 17 sites in 8 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Hyperoxaluria Type 1 (PH1)
CountriesFrance, Germany, Israel, Netherlands, Switzerland, United Arab Emirates, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartNov 2018
Primary CompletionNov 2019
Study CompletionJan 2024
TodayJul 2026
First PostedSep 21, 2018
Enrollment StartNov 27, 2018
Primary CompletionNov 5, 2019
Study CompletionJan 12, 2024
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.8 years ago
Interventions
Placebodrug
Placebo by SC injection
Lumasirandrug
Lumasiran by SC injection